Aileron Therapeutics
在场
Aileron Therapeutics 是一家在股票代码 ALRN (US) 下上市的公司。
涉及Aileron Therapeutics的并购和融资。
高管
查看带有其 8 名主要高管的组织结构图
Aileron Therapeutics 搜索最多的简介
- Brian Windsor, Director, President and Chief Executive Officer
- Reinhard Ambros, Director
- Josef Von Rickenbach, Chairman of the Board
高管在Aileron Therapeutics变化
- Brian Windsor 曾任 Chief Operating Officer and President, 现升职为 Director, President and Chief Executive Officer (新闻发布的2024三月13号).
创建提醒
跟踪 Aileron Therapeutics 的高管变动
生物技术
Aileron Therapeutics 拥有 2,282 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Endeavor BioMedicines 刚刚宣布为 132 筹款数百万美元。 (公布2024四月25号).
- Metsera 刚刚宣布为 290 筹款数百万美元。 (公布2024四月23号).
- Histogen has filed for bankruptcy protection (公布2024四月19号).
生物技术 行业的其他推荐联系人
消息
Aileron Therapeutics 的最新新闻稿
- Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer ― Aileron
- Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022 ― Aileron
- Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer ― Aileron
- Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer ― Aileron Therapeutics
- Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference ― Aileron Therapeutics
- Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022 ― Aileron Therapeutics
- Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual
- Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights ― Aileron Therapeutics
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights ― Aileron Therapeutics
- Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference ― Aileron Therapeutics
- View more press releases Close
通过电子邮件
